EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Effect of adding PCSK9 inhibitors to lipid‐lowering interventions on arterial stiffness: A systematic review and meta‐analysis

I Cavero-Redondo iD, N Moreno-Herraiz, A Del Saz-Lara, I Otero-Luis, J I Recio-Rodriguez, A Saz-Lara

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14269 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von I Cavero-Redondo und 5 weiteren Autor:innen. Beteiligte Einrichtung: CarVasCare Research Group (2023-GRIN-34459), Faculta de Enfermería de Cuenca, Universidad de Castilla-La Mancha, Cuenca, Spain. Hauptthemen laut MEDLINE: Hypercholesterolemia, PCSK9 Inhibitors, Pulse Wave Analysis, Vascular Stiffness. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atherosclerosis, a leading cause of mortality, necessitates effective management of hypercholesterolemia, specifically elevated low‐density lipoprotein cholesterol (LDL‐C). The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has revolutionised lipid‐lowering. PCSK9i demonstrates substantial LDL‐C reduction and cardiovascular benefits, particularly in statin‐intolerant or nonresponsive individuals. However, the potential pleiotropic effects of PCSK9i, especially on arterial stiffness, remain a subject of investigation. This systematic review and meta‐analysis seek to provide a nuanced understanding of the potential pleiotropic effects of PCSK9i, specifically on arterial health. The primary objective was to analyse the influence of PCSK9i on arterial stiffness, extending beyond traditional lipid‐lowering metrics and contributing to a more comprehensive approach to cardiovascular risk reduction.

Methods

A systematic search was conducted across major databases, clinical trial registries and grey literature. Inclusion criteria comprised adults in prospective cohort studies undergoing PCSK9i augmentation in lipid‐lowering therapy, with a focus on arterial stiffness measured by pulse wave velocity (PWv). Random‐effects meta‐analyses, sensitivity analyses and meta‐regression models were employed to assess the pooled effect of adding PCSK9i to lipid‐lowering interventions on arterial stiffness.

Results

Five studies (158 participants) met the inclusion criteria, demonstrating a significant reduction in PWv (mean difference: −2.61 m/s [95% CI: −3.70, −1.52]; ES: −1.62 [95% CI: −2.53, −.71]) upon adding PCSK9i to lipid‐lowering interventions. Subgroup analysis and meta‐regression models suggested potential sex‐based and baseline PWv‐dependent variations, emphasising patient‐specific characteristics.

Conclusion

The meta‐analysis provides robust evidence that adding PCSK9i to lipid‐lowering interventions significantly improves arterial stiffness, indicating broader vascular benefits beyond LDL‐C reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercholesterolemiaPCSK9 InhibitorsPulse Wave AnalysisVascular StiffnessHumansAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtherosclerosisCholesterol, LDLDrug Therapy, CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9

Stichwörter der Autor:innen

PCSK9 inhibitorsadultsarterial stiffnesslipid‐lowering interventionspulse wave velocity

Substanzen

Antibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsalirocumabevolocumabPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • CarVasCare Research Group (2023-GRIN-34459), Faculta de Enfermería de Cuenca, Universidad de Castilla-La Mancha, Cuenca, Spain.
  • Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile.
  • Laboratory of Epigenetics of Lipid Metabolism, Instituto Madrileño de Estudios Avanzados (IMDEA)-Alimentación, CEI UAM+CSIC, Madrid, Spain.
  • Laboratory of Functional Foods, Instituto Madrileño de Estudios Avanzados (IMDEA)-Alimentación, CEI UAM+CSIC, Madrid, Spain.
  • Faculty of Nursing and Physiotherapy, University of Salamanca, Salamanca, Spain.
  • Primary Care Research Unit of Salamanca (APISAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

ORCID-Profile: I Cavero-Redondo

Förderung

  • European Regional Development Fund

Zitieren

APA

Cavero-Redondo, I., Moreno-Herraiz, N., Del Saz-Lara, A., Otero-Luis, I., Recio-Rodriguez, J. I., & Saz-Lara, A. (2024). Effect of adding PCSK9 inhibitors to lipid‐lowering interventions on arterial stiffness: A systematic review and meta‐analysis. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14269

Vancouver

Cavero-Redondo I, Moreno-Herraiz N, Del Saz-Lara A, Otero-Luis I, Recio-Rodriguez JI, Saz-Lara A. Effect of adding PCSK9 inhibitors to lipid‐lowering interventions on arterial stiffness: A systematic review and meta‐analysis. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14269

BibTeX
@article{CaveroRedondo2024,
  author = {Cavero-Redondo, I and Moreno-Herraiz, N and Del Saz-Lara, A and Otero-Luis, I and Recio-Rodriguez, J I and Saz-Lara, A},
  title = {Effect of adding PCSK9 inhibitors to lipid‐lowering interventions on arterial stiffness: A systematic review and meta‐analysis},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14269}
}
Kostenlos starten →